Institute for Cancer Research

Kjetil Taskén
Institute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

See introductory video with welcome to the ICR 

See full video covering all of ICR and its Departments 

Publication overview

Annual reports


Current news and events

Researcher of the year 2021 at the Institute for Cancer Research:Kay Oliver Schink

Kay Schink – project group leader at Institute for Cancer Research - was on December 15th awarded the prize Research of the Year from the leadership at ICR for his groundbreaking scientific contributions.

The award of 100 000 NOK is financed by the Radium Hospital Foundation (Radiumhospitalets legater) and is a personal scholarship for stimulating further excellence in research. 

Employee of the year 2021, the Institute for Cancer Research: Idun Dale Rein

Idun Dale Rein – service leader of the flow cytometry core facility - was on December 15th awarded the prize Employee of the Year 2021 from the leadership at the Institute for Cancer Research (ICR). Rein works in the Department of Core Facilities, Unit for flow cytometry. The committee describes Idun Dale Rein as a very competent and service-minded employee who helps customers with everything from choosing the right probe to experimental set-up and interpretation of data. 

Nature Biotechnology publication:New immunotherapy for cancer based on the mechanism of transplant rejection

From left: Muhammad Ali, Eirini Giannakopoulou (shared first authors) and Johannna Olweus (senior author)
From left: Muhammad Ali, Eirini Giannakopoulou (shared first authors) and Johannna Olweus (senior author)

A team of scientists at the University of Oslo, Oslo University Hospital (OUH) Radiumhospitalet and Karolinska Institutet, led by Professor Johanna Olweus, has developed a new type of immunotherapy for cancer. The new treatment makes the patient’s immune cells “believe” that cancer is a transplanted organ that should be rejected.

The results were published in Nature Biotechnology, one of the most prestigious cross-disciplinary scientific journals, on 6 December 2021.

IMPRESS-Norway and Illumina enter into cooperation

Hege Russnes
Hege Russnes

Illumina, one of the largest international diagnostic companies in sequencing, has recently signed a collaboration contract with the national cancer study IMPRESS-Norway. 

"Securing high-quality tissue biopsies can be both challenging and time-consuming," says Hege Russnes, Senior Consultant in Pathology, OUH and Head of the Infrastructure for Precision Diagnostics for cancer (InPreD). " We are grateful to Illumina's support of this project and excited about the opportunity to investigate the match towards the CGP results from the tissue samples."

Funded by 128 mill NOK:Centre for Clinical Treatment Research - MATRIX

Åslaug Helland, centre leader
Åslaug Helland, centre leader

The Research Council of Norway and the Norwegian Cancer Society have allocated 128 mill. NOK for a Centre for Clincial Treatment Research for treatment of cancer. 

"This funding is an important contribution to Norwegian cancer research and will ensure that more patients will be included into clinical trials. The aim is new and better treatment alternatives for hard-to-treat cancers. We will develop next generation diagnostics and treatment for increased overall survival and quality of life for cancer patients all over Norway" says Åslaug Helland, leader of the centre.


Units and subpages

View all subunitsHide all subunits